Connect with us

Technology

Beckman Coulter Diagnostics Expands Alzheimer’s Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay

Published

2 months ago

on

CE-marked Access p-Tau217 blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline across Europe

Brain Derived pTau217 RUO assay selectively detects brain-derived pTau217 unlocking new neurodegenerative insights through high-specificity research of amyloid and tau pathology

Powered by the DxI 9000 Immunoassay Analyzer, this expanding portfolio enables laboratories to
provide diverse testing capabilities within a single, high-throughput, high sensitivity solution

BREA, Calif., July 7, 2026 /PRNewswire/ — Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline. The company also introduced its high-specificity Access BD-pTau217 Research Use Only (RUO) assay at the Alzheimer’s Association International Conference (AAIC) 2026 in London.

The CE Mark represents a significant milestone in expanding access to blood-based p-Tau217 testing in Europe and additional CE-recognizing markets, supporting laboratories and clinicians with a scalable, automated solution. Building on this clinical progress, the newly launched RUO assay is designed to further advance research into disease biology. Both assays are enabled by the DxI 9000 Immunoassay Analyzer, ensuring laboratories can efficiently manage clinical and research tests on a single high-precision analyzer.

Scaling Access to Alzheimer’s Disease Blood Testing with CE-Marked, Automated p-Tau217 Assay

The new CE Marked assay measures phosphorylated tau (p-Tau217), a well-established biomarker associated with Alzheimer’s disease, enabling scalable assessment in routine clinical settings. Blood-based approaches can complement existing diagnostic pathways by offering a more accessible, operationally scalable method for evaluating Alzheimer’s-related pathology within laboratory workflows.

“Our CE-marked Access p-Tau217 assay brings a well-established Alzheimer’s biomarker into routine clinical workflows, enabling laboratories to scale blood-based evaluation of disease pathology more efficiently,” said Dr. Chris Bird, Chief Medical Officer at Beckman Coulter Diagnostics. “By making testing more accessible and operationally scalable, it helps integrate biomarker-based assessment into everyday clinical practice.”

Beckman Coulter Diagnostics developed the Access p‑Tau217 assay using AlzPath’s antibody, cited in more than 200 peer‑reviewed publications, underscoring strong scientific validation. As demand for Alzheimer’s disease diagnostics grows, blood‑based testing will play an increasingly important role in enabling consistent evaluation across clinical settings. This milestone marks the translation of validated biomarker science into Beckman Coulter’s first clinical, blood‑based assay for amyloid pathology in patients with signs and symptoms of cognitive decline, accelerating the path from research insight to real‑world use.

Introducing High-Specificity Brain-Derived pTau217 Assay for Research Use

In addition to the CE-marked IVD assay, Beckman Coulter Diagnostics is introducing its Access BD-pTau217 RUO assay, designed to selectively detect the short form (or low molecular weight) pTau217 in blood samples using the DxI 9000 Analyzer. By targeting the short form of pTau217 originating in the brain, the new research assay is designed to enhance biological specificity and provide precise characterization of central nervous system phosphorylated Tau217 signals in blood.

“By focusing on brain-derived pTau217, this assay is designed to deliver a higher level of biological specificity, helping researchers more precisely identify tau pathology in blood most relevant to their studies,” said Dr. Jeremiah Hinson, Chief Scientific Officer for Neurodegenerative Diseases at Danaher . “This increased specificity can bolster confidence in studying Alzheimer’s disease staging and support new insights into the biological inflection points that define how the disease evolves.”

Early research findings suggest that higher biological specificity may help improve interpretability of biomarker detection in complex research datasets and support clearer differentiation of tau-related pathology in Alzheimer’s disease.

“In the AIBL Study of Ageing, plasma pTau217 demonstrated strong performance as a blood‑based marker of Alzheimer’s pathology,” said James Doecke, PhD, Principal Research Scientist, Commonwealth Scientific and Industrial Research Organisation and the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing. “When evaluated alongside amyloid and tau PET imaging, brain‑derived pTau217 showed additional biological specificity, particularly for research focused on tau‑related staging. These findings reinforce the role of pTau217 as a cornerstone biomarker while highlighting the potential value of higher biological specificity for improving clarity in Alzheimer’s disease research.”

Advancing Alzheimer’s Disease Testing Through the DxI 9000 Immunoassay System

Beckman Coulter Diagnostics is advancing its Alzheimer’s disease portfolio on the DxI 9000 Analyzer, a highly sensitive, scalable platform designed to detect low-abundance biomarkers with consistency. By enabling both the CE-marked Access p-Tau217 assay and the Access BD-pTau217 (RUO), as well as existing Access GFAP (RUO), Access BD-Tau (RUO), Access NfL (RUO), Access Beta-Amyloid 1-42 (RUO) and Access apoE ε4 (RUO) assays to run on a common platform, laboratories can integrate diverse testing capabilities within a consistent, high-throughput workflow.

“High-sensitivity detection, robust assays, and operational scalability are critical as blood-based biomarkers become more widely adopted,” said Dr. Nick Culshaw, Vice President and Managing Director, Clinical Chemistry and Immunoassay Business at Beckman Coulter Diagnostics. “By anchoring our Alzheimer’s disease portfolio on the DxI 9000 Analyzer, we are enabling laboratories to access an expanding set of biomarker insights, from clinical assessment to research applications, within a single system.”

The DxI 9000 Analyzer combines analytical sensitivity with operational flexibility, allowing laboratories to support a growing range of biomarker applications, from routine clinical evaluation to advanced research into disease biology, without compromising performance or efficiency. This unified platform approach helps ensure consistency in assay execution while enabling expansion into emerging markers across neurodegenerative diseases as scientific understanding evolves.

Beckman Coulter Diagnostics at AAIC 2026

At AAIC 2026 in London, Beckman Coulter Diagnostics will highlight new data advancing blood-based testing for Alzheimer’s disease through a focused program of scientific presentations and expert engagement.

The company will present five posters on pTau217 and novel biomarker approaches, including data demonstrating improved detection of Alzheimer’s pathology and enhanced performance using biomarker ratios and next-generation assays. Featured research spans clinical utility, disease staging and assay innovation, as well as late-breaker findings on pTau217/Aβ42 and BD‑Tau ratio approaches.

Key on-site engagements include:

Enabling Alzheimer’s Biological Staging with Blood Based Biomarkers, featuring James Doecke, PhD, and Charbel Abou-Diwan, PhD, Senior Director, Medical & Scientific Affairs, Beckman Coulter Diagnostics, July 13, 10:30–11:00 AMImproving real-world representation in Alzheimer’s disease research and treatment, Opening remarks by Jeremiah Hinson, M.D., Ph.D., followed by Sid E. O’Bryant, Ph.D.; Suzanne Craft, Ph.D.; Carlos Cruchaga, Ph.D.; Michelle Mielke, Ph.D.; Charlotte Teunissen, Ph.D.; and Michael Weiner, M.D. July 13, 12:30–1:45 PM 

Attendees can also visit the Beckman Coulter Diagnostics booth #921 to connect with experts and explore how high-throughput immunoassay platforms are supporting scalable adoption of blood-based biomarker testing.

About Beckman Coulter. Inc.

Beckman Coulter Diagnostics is a global leader in advanced diagnostics, helping laboratories transform insight into impact through science, technology, and collaboration. For more than 90 years, the company has challenged convention to elevate the role of the diagnostic laboratory, accelerating ideas from discovery to real world clinical outcomes. Guided by its mission to Relentlessly Reimagine Healthcare, One Diagnosis at a Time, Beckman Coulter Diagnostics delivers trusted solutions for complex clinical testing across hospitals, reference laboratories, and physician office settings worldwide, supported by an extensive clinical menu, scalable automation, actionable informatics, and lab performance optimization services. Part of Danaher, a global science and technology innovator, Beckman Coulter Diagnostics draws on a connected network of specialized companies—combining shared capabilities, scale, and expertise to help solve some of healthcare’s most complex challenges, together.  Headquartered in Brea, California, the company employs more than 11,000 associates globally.

Follow and connect with Beckman Coulter via LinkedIn, X, and Facebook

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

The Access p‑Tau217 assay is CE‑marked under IVDR (EU) 2017/746 (CE 2797)

© 2026 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. The Danaher trademark is a proprietary mark of Danaher Corporation. 3092-GBL-EN

View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-expands-alzheimers-portfolio-with-ce-marked-p-tau217-blood-test-and-new-high-specificity-research-assay-302818858.html

SOURCE Beckman Coulter Inc

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

X Square Robot showcases the Power of “One Model, Many Applications” at WRC 2026

Published

29 minutes ago

on

August 25, 2026

By

Highlighting the breadth of what WALL-B can enable and the depth of performance it can sustain in the physical world.

BEIJING, Aug. 25, 2026 /PRNewswire/ — X Square Robot, a Shenzhen-based embodied AI company, concluded its participation at the 2026 World Robot Conference (WRC) in Beijing, putting its “one model, many applications” approach to practice across multiple robotic platforms and real-world tasks. Powered by WALL-B, the company brought this approach into a range of physical environments, while extending its first logistics livestream on Aug 12 into a five-hour challenge during WRC.

At the conference, X Square showcased its WALL-B technology across several robotic platforms. In a home environment, two wheeled humanoid robots responded to spoken commands. It performed tasks including organizing household items, retrieving and delivering objects, cleaning, watering plants and handling pet-related chores. Using coordinated two-arm manipulation and obstacle avoidance, the robot moved between rooms and carried out the requested tasks.

The exhibition demonstration formed part of X Square’s broader effort to deploy robots in real homes. In March, the company partnered with Chinese local-services platform 58.com to launch a home-cleaning service, with robots working alongside professional cleaners during household visits. In May, X Square began placing robots with participating households for extended in-home service through its “X Family Member Program.”

Elsewhere at the conference, a 22-degree-of-freedom, five-fingered dexterous hand completed a multi-stage fan-unboxing task powered by WALL-B. With its view partially obstructed by the box, the system opened the packaging, removed the fan from a confined space, placed it on a table, turned the fan on and visually verified that it was running. A separate dual-arm system responded to visitors’ natural-language requests by selecting flowers of the specified color and arranging them in a vase. It adjusted its grip and positioning to handle flexible stems and deformable flowers, and replanned its movements when the flower basket or vase was moved during the task.

X Square extended its focus on real-world deployment into logistics. The WALL-B-powered system is already operating on a live parcel-sorting line and is designed to support continuous, round-the-clock operation. The WRC demonstration provided a public test of that capability. During the challenge, the WALL-B-powered system sorted 10,000 parcels in 5 hours, 14 minutes and 1 second, translating into an average throughput of 1,911 parcels an hour, or about 1.88 seconds per parcel.

During the challenge, the robots handled parcels that varied in size, shape, material and position. The system had to repeatedly identify, grasp, orient and sort the items, while correcting unsuccessful actions and responding to changes on the conveyor. Maintaining its throughput over thousands of parcels offered a measure of the consistency and endurance required in commercial logistics operations.

“Embodied AI requires a foundation model built specifically for the physical world, in parallel with the foundation models developed for the digital world. At X Square, our aim is to develop a common intelligence foundation that can operate across different robots, tasks and physical environments, while continuing to improve through real-world deployment,” said Wang Qian, founder and CEO of X Square Robot.

Taken together, the demonstrations reflected X Square’s broader view that embodied intelligence should not be tied to a single robot, task or environment. The company said it will continue integrating models and robotic hardware as it expands into additional home, logistics and industrial applications.

For more information, visit https://x2robot.com/.

About X Square Robot

X Square Robot focuses on developing its own general-purpose embodied AI models and robotic hardware. As a leading Chinese company in the field, it has pioneered the deployment of general-purpose embodied AI in real-world settings such as homes and logistics.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/x-square-robot-showcases-the-power-of-one-model-many-applications-at-wrc-2026-302858862.html

SOURCE X Square Robot

Continue Reading

Technology

European Telcos Push EMEA 5G Mobile Core Revenue to a New High in 2Q 2026, According to Dell’Oro Group

Published

1 hour ago

on

August 25, 2026

By

Sharp IMS Revenue Contraction Brings Down Market

REDWOOD CITY, Calif., Aug. 24, 2026 /PRNewswire/ — According to a recently published report from Dell’Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, 5G Mobile Core Network (MCN) revenue in EMEA grew over 30 percent in 2Q 2026, contributing more revenue to the worldwide 5G MCN market than any other region.

“So far in 2026, eighty percent of the operators to have launched 5G Standalone (SA) networks for consumer services have been in Europe,” stated Siân Morgan, Sr. Director at Dell’Oro Group. “This helped EMEA 5G MCN revenue to reach a high-water mark in 2Q 2026, and we expect this region will keep expanding in the coming quarters.

“The growth in 5G MCN occurred despite an escalation in server prices causing mobile network operators to scrutinize the cost of network projects. On the other hand, IMS revenue contracted for the third quarter in a row, with most regions seeing a drop in Voice core revenue,” continued Morgan.

Additional highlights from the 2Q 2026 Mobile Core Network and Multi-Access Edge Computing Report include:

MCN market dynamics were stable, with Huawei, Ericsson and Nokia growing MCN revenue in alignment with total market expansion.
4G Wireless Packet Core revenue outpaced the market for the third quarter in a row, driven by mobile network operators that have not yet moved to 5G SA.
In nominal terms, revenue from 5G MCN has still not reached the levels achieved by 4G MCN, with the pressure to automate operations and grow ARPU counterbalanced by the rising cost of infrastructure.

About the Report
The Dell’Oro Group Mobile Core Network & Multi-Access Edge Computing Quarterly Report offers complete, in-depth coverage of the market with tables covering manufacturers’ revenue, shipments, and average selling prices for Traditional Packet Core, Evolved Packet Core, 5G Packet Core, Policy, Subscriber Data Management, Signaling, Circuit Switched Core, and IMS Core by geographic regions. To purchase this report, please contact us at dgsales@delloro.com.

About Dell’Oro Group
Dell’Oro Group is a market research firm that specializes in strategic competitive analysis in the telecommunications, security, enterprise networks, and data center infrastructure markets. Our firm provides in-depth quantitative data and qualitative analysis to facilitate critical, fact-based business decisions. For more information, contact Dell’Oro Group at +1.650.622.9400 or visit https://www.delloro.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/european-telcos-push-emea-5g-mobile-core-revenue-to-a-new-high-in-2q-2026-according-to-delloro-group-302858820.html

SOURCE Dell’Oro Group

Continue Reading

Technology

YADEA and J&T Express Philippines Sign Strategic Agreement to Advance Electric Last-Mile Delivery

Published

1 hour ago

on

August 25, 2026

By

TAGUIG CITY, Philippines, Aug. 25, 2026 /PRNewswire/ — Yadea Philippines and J&T Express have announced a strategic partnership to accelerate the adoption of electric vehicles in the local logistics sector. Manila will serve as the pilot with 1,000 units rolling out initially, followed by nationwide expansion.

As the global No.1 electric two-wheeler brand for nine consecutive years, Yadea operates over 70 branded sales and service centers, with flagship models like EPOC and CL8. Partnering with J&T Express, a leading Philippine courier, will accelerate Yadea’s entry into the local logistics market. Together, they aim to optimize logistics and drive a greener, low-carbon future for express delivery, reflecting the companies’ shared commitment to sustainable urban mobility and environmental stewardship.

YADEA ST13 is an electric delivery tricycle designed for high-frequency, short-distance commercial delivery scenarios. It integrates energy-efficient transport systems purpose-built for high-frequency urban dispatch. The unit features a weight-reducing mesh cargo box that directly optimizes battery range, paired with premium A+ grade puncture-resistant steel-wire tires designed for continuous delivery operational capability.

Yadea General Manager of the Philippines Wang Chun stated, “This cooperation reflects a deep synergy between product capability and logistics networks, representing a practical response to the country’s demand for green transportation. We hope our locally tailored electric vehicles allow delivery personnel to ride with greater peace of mind and operate more efficiently, injecting tangible momentum into low-carbon urban logistics.”

J&T Express Philippines National Capital Region Key Account Manager Mary Andaya stated, “Through this collaboration, we are actively integrating electric vehicle solutions into our last-mile operations. This initiative optimizes our daily workflow while aligning with our shared direction of collaborating on the large-scale adoption of electric tricycles for deliveries to enhance delivery efficiency within the local logistics sector.”

About YADEA

YADEA is a leading electric mobility brand and has ranked No.1 globally in electric two-wheeler sales for nine consecutive years. Driven by innovation, YADEA provides electric two-wheelers, electric tricycles and other mobility solutions to users around the world through its integrated capabilities in R&D, manufacturing, products channels and services.

About J&T Express Philippines

J&T Express Philippines, a nationwide logistics provider established in 2019, offers express delivery services via land, air, and sea. The company operates automated distribution centers and maintains extensive trucks and delivery services that run 24/7, ensuring that packages are safely delivered across the Philippines.

Contact:
media@yadea.com

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/yadea-and-jt-express-philippines-sign-strategic-agreement-to-advance-electric-last-mile-delivery-302858830.html

SOURCE Yadea Philippines

Continue Reading

Trending